Rehmann Capital Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $918K | Sell |
1,846
-193
| -9% | -$85.5K | 0.04% | 287 |
|
|
2026
Q1 | $910K | Buy |
2,039
+102
| +5% | +$47.6K | 0.05% | 266 |
|
|
2025
Q4 | $879K | Buy |
1,937
+61
| +3% | +$26.3K | 0.05% | 269 |
|
|
2025
Q3 | $735K | Buy |
1,876
+168
| +10% | +$70.2K | 0.04% | 299 |
|
|
2025
Q2 | $760K | Buy |
1,708
+144
| +9% | +$66.4K | 0.05% | 268 |
|
|
2025
Q1 | $758K | Buy |
1,564
+48
| +3% | +$22.4K | 0.05% | 267 |
|
|
2024
Q4 | $610K | Sell |
1,516
-436
| -22% | -$202K | 0.04% | 305 |
|
|
2024
Q3 | $906K | Sell |
1,952
-747
| -28% | -$359K | 0.06% | 228 |
|
|
2024
Q2 | $1.27M | Sell |
2,699
-81
| -3% | -$35.2K | 0.09% | 172 |
|
|
2024
Q1 | $1.16M | Buy |
2,780
+282
| +11% | +$119K | 0.09% | 185 |
|
|
2023
Q4 | $1.02M | Buy |
2,498
+290
| +13% | +$107K | 0.08% | 188 |
|
|
2023
Q3 | $768K | Hold |
2,208
| – | – | 0.07% | 214 |
|
|
2023
Q2 | $777K | Sell |
2,208
-361
| -14% | -$122K | 0.07% | 230 |
|
|
2023
Q1 | $809K | Sell |
2,569
-27
| -1% | -$8.1K | 0.08% | 226 |
|
|
2022
Q4 | $750K | Buy |
2,596
+68
| +3% | +$20.7K | 0.08% | 224 |
|
|
2022
Q3 | $732K | Buy |
2,528
+220
| +10% | +$63.3K | 0.08% | 216 |
|
|
2022
Q2 | $650K | Sell |
2,308
-492
| -18% | -$132K | 0.07% | 234 |
|
|
2022
Q1 | $745K | Buy |
2,800
+392
| +16% | +$93K | 0.07% | 247 |
|
|
2021
Q4 | $529K | Sell |
2,408
-165
| -6% | -$32.1K | 0.05% | 305 |
|
|
2021
Q3 | $466K | Sell |
2,573
-81
| -3% | -$15.8K | 0.04% | 335 |
|
|
2021
Q2 | $502K | Buy |
2,654
+551
| +26% | +$115K | 0.05% | 307 |
|
|
2021
Q1 | $451K | Buy |
2,103
+279
| +15% | +$61.3K | 0.05% | 305 |
|
|
2020
Q4 | $431K | Sell |
1,824
-204
| -10% | -$46.8K | 0.05% | 295 |
|
|
2020
Q3 | $552K | Buy |
2,028
+109
| +6% | +$30.1K | 0.07% | 229 |
|
|
2020
Q2 | $557K | Buy |
1,919
+398
| +26% | +$108K | 0.08% | 221 |
|
|
2020
Q1 | $362K | Buy |
+1,521
| New | +$349K | 0.06% | 251 |
|
|
2019
Q3 | $330K | Buy |
1,949
+1,509
| +343% | +$267K | 0.04% | 238 |
|
|
2019
Q2 | $80.7K | Sell |
440
-1
| -0.2% | -$175 | 0.01% | 683 |
|
|
2019
Q1 | $81.1K | Buy |
441
+32
| +8% | +$5.91K | 0.01% | 659 |
|
|
2018
Q4 | $67.8K | Buy |
409
+75
| +22% | +$13K | 0.01% | 504 |
|
|
2018
Q3 | $64.4K | Sell |
334
-42
| -11% | -$7.48K | 0.01% | 712 |
|
|
2018
Q2 | $63.9K | Sell |
376
-1,022
| -73% | -$158K | 0.01% | 698 |
|
|
2018
Q1 | $228K | Buy |
+1,398
| New | +$228K | 0.04% | 342 |
|
Other funds holding VRTX
Rehmann Capital Advisory Group's VRTX Position: Q2 2026 in Review
Rehmann Capital Advisory Group reduced its Vertex Pharmaceuticals (VRTX) stake by 9.5% in Q2 2026, selling an estimated $85.5K and leaving 1,846 shares worth $918K. The position accounts for 0.04% of the portfolio, ranked #287.
Rehmann Capital Advisory Group first reported a position in VRTX in Q1 2018 and has held it in 33 quarters since. The position peaked at $1.27M in Q2 2024. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Rehmann Capital Advisory Group held 1,846 shares of Vertex Pharmaceuticals worth $918K as of Q2 2026.
- Rehmann Capital Advisory Group sold 193 Vertex Pharmaceuticals shares in Q2 2026, an estimated $85.5K.
- Vertex Pharmaceuticals made up 0.04% of Rehmann Capital Advisory Group's portfolio in Q2 2026, its #287 holding.
- Rehmann Capital Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
- Rehmann Capital Advisory Group's Vertex Pharmaceuticals position peaked at $1.27M in Q2 2024.
- 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Rehmann Capital Advisory Group's 13F filing for Q2 2026, filed 20 Aug 2026.